‘Disruptor’ Mark Cuban Takes Aim At US Industry Barriers
Billionaire Entrepreneur Says Trust And Transparency Will Lift Reputation Of Generics
Executive Summary
During a lively discussion at the AAM’s Access! conference in Orlando, billionaire entrepreneur Mark Cuban set out how he plans to use his Cost Plus Drugs company to disrupt the generics sector while also lifting its reputation by increasing trust and transparency among patients.
You may also be interested in...
Coherus Plots ‘Lowest Price Adalimumab’ With Huge Discount, Ties Up With Mark Cuban
Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.
Celltrion CCO On The Big US Build-Up, Direct Sales Model
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.
Generics Bulletin Editor’s Picks For Q1 2023
Looking back over the first quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from January to March that include the launch of the first US Humira biosimilar, new leadership at the top of some of the industry’s biggest players, annual results and strategy updates, and multiple major industry conferences – as well as the launch of our annual awards.